Exploring the risk factors for differences in the cumulative incidence of coeliac disease in two neighboring countries

Simre, Kart

2016-11


http://hdl.handle.net/10138/228786
https://doi.org/10.1016/j.dld.2016.06.029

Downloaded from Helda, University of Helsinki institutional repository.

This is an electronic reprint of the original article.

This reprint may differ from the original in pagination and typographic detail.

Please cite the original version.
Alimentary Tract

Exploring the risk factors for differences in the cumulative incidence of coeliac disease in two neighboring countries: the prospective DIABIMMUNE study

Kärt Simre a,b, Oivi Uibo b,c, Aleksandr Peet b,c, Vallo Tillmann b,c, Pille Kool c, Anu-Maaria Hämäläinen d, Taina Härkönen e,f, Heli Siljander e,f, Suvi Virtanen g,h,i, Jorma Iloinen j, Mikael Knip e,i,k, Raivo Uibo a,*, The DIABIMMUNE Study Group1

a Department of Immunology, Institute of Biomedicine and Translational Medicine, University of Tartu, Tartu, Estonia
b Children’s Clinic of Tartu University Hospital, Tartu, Estonia
c Department of Pediatrics, University of Tartu, Tartu, Estonia
d Jorvi Hospital, Helsinki University Hospital, Espoo, Finland
e Children’s Hospital, University of Helsinki and Helsinki University Hospital, Helsinki, Finland
f Research Programs Unit, Diabetes and Obesity, University of Helsinki, Helsinki, Finland

Article history:
Received 15 March 2016
Accepted 23 June 2016
Available online 6 July 2016

Keywords:
Breastfeeding
Coeliac disease
Early feeding
Early infections

1. Introduction

Coeliac disease (CD) is a dietary gluten induced immune-mediated systemic disorder that occurs in genetically predisposed people. It is characterized by variable clinical manifestations, CD-specific autoantibodies, HLA-DQ2 (DQA1*05-DQB1*02) or HLA-DQ8 (DQB1*03:02) haplotypes and enteropathy [1].

In recent decades the prevalence of CD has increased worldwide [2] and is now estimated to range between 1% [3,4] and 3% [5] in the Western countries. The frequency has also increased in Estonia and in Finland, the two neighbouring countries, with marked differences in the socio-economic background until the early 1990s. It was shown that the age-standardized incidence rate of childhood CD in Estonia increased dramatically during a 35-year period: from 0.10 in 1976–1980 to 3.14 per 100,000 person-years in 2006–2010.
follow-up programme with planned visits at the age of 3, 6, 12, 18, 24 and 36 months (±1 month). Finns had higher frequency of HLA risk genotypes (23.0% vs 15.7%), but Estonians consented more eagerly (80.5% vs 58.6%). Both came to the 3 year visit with the same eagerness. As more Finnish children did not give the consent for follow-up and we do not have any information about them and their diseases, we cannot totally exclude that this could affect our results. Accordingly one might suppose that there are even bigger differences between Estonia and Finland. At the first study visit the parents were given a diary in which they were asked to report data about infections, use of medications, allergies, vaccinations and environmental exposures. Data on breastfeeding and on the introduction of complementary foods and their character was also registered. All diary data was transferred to a central database at each visit.

In the YCC, 1681 children from Estonia and 1575 children from Finland were studied at the age of 3 years, and 1363 (81%) and 1384 (88%) children, respectively, attended the follow-up visit at the age of 5 years. In addition, 250 children from Estonia and 448 children from Finland were also studied at the age of 4 years. Invitation letter to participate in the study was sent to all 3-years children living in South Estonia, whereas the Finnish cohort comprising 3-year old children was recruited among children born in the Jorvi Hospital whose family was still living in the Espoo region. All participants were genotyped for HLA but no selection was based on the genotype. A study diary was given to the parents at the initial visit with the request that they should fill in information on food intake, infections, use of medications, vaccinations, allergies and environmental exposures. Information on the history of breastfeeding was collected at the first visit.

Non-fasting blood samples were collected by venipuncture from all participants at every visit. Serum was separated by centrifugation and stored in aliquots at −70 °C for further use. For each blood sample, CD related antibody analyses were performed in accordance with a specific protocol. If the antibody test result indicated suspicion of CD, the child was invited for gastrodudenoscopy and small intestinal biopsy. All children with biopsy-confirmed CD were included in the current analysis. For every child with CD, one control child was selected (except for one child in the YCC who had two controls – one at the age of 3 and another at the age of 5 years). The control children were selected from the DIABIMMUNE Study cohorts and matched for the CD-specific HLA DR/DQ genotype, country of birth, age and gender.

2. Materials and methods

2.1. Study design and population

Children were recruited into the study cohort as part of the international prospective observational DIABIMMUNE Study. The DIABIMMUNE Study set out to assess the role of the hygiene hypothesis in the development of type 1 diabetes (T1D) and other immune-mediated diseases. The study was carried out in Estonia, Finland and Russian Karelia from September 2008 to October 2013. The study included two cohorts: a birth cohort (BC) observed from birth up to the age of 3 years and a cohort of young children (YCC) examined for the first time at the age of 3 years and followed up to the age of 5 years.

Initially, 2714 infants from maternity hospitals in Estonia and 3105 in Finland were recruited to the BC. Cord blood samples were taken from all children wherever it has been technically possible and parents have given written informed consent. All children were analyzed for T1D/CD associated HLA DR/DQ alleles as described earlier [22]. Four hundred and twenty-six Estonian children and 713 Finnish children carried an eligible HLA genotype (DR3-DQ2 (DQA1*05-DQB1*02)/DR4-DQ8 (DRB1*04:01/2/4/5-DQA1*03-DQB1*03:02) heterozygosity, or either DR4-DQ8 or DR3-DQ2 haplotype alone without any haplotypes protecting for T1D). Children with eligible HLA were invited for a follow-up study. In total, 258 children in Estonia (61% of eligible) and 305 in Finland (43% of eligible) completed the 3-year
sample was haemolytic, or if the IgA-tTG assay could not detect any IgA (“low RU” as a sign of possible IgA deficiency), the sera were retested for IgG-deamidated gliadin and IgG-tTG antibodies by ImmunoCAP EliA, using the same cut-off values for positivity as in the case of IgA-tTG EliA.

2.3. Diagnosis of CD

The diagnosis of CD was made in accordance with the European Society for Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN) guidelines [11]—positive IgA-tTG antibodies and a biopsy of the small intestine with an abnormal microscopic finding. The small intestine microscopic findings were classified in accordance with the Marsh classification modified by Oberhuber [26].

2.4. Statistical analysis

Statistical analysis was performed with the R software for Windows (The R Foundation for Statistical Computing, Vienna, Austria). The cumulative incidence of CD was calculated by dividing the number of new histologically proven CD cases by the number of the study population during the study period. The incidence rate was calculated by dividing the number of new histologically proven CD cases by the sum of the time each person was observed, totaled for all persons. For statistical analysis of the cumulative incidence, the Fisher’s exact test or the Chi square test was applied. Comparisons between the CD group and the control group were performed with the Mann–Whitney–Wilcoxon test. A P-value <0.05 was considered significant.

2.5. Ethical considerations

The study was conducted in accordance with the ethical guidelines established by the Declaration of Helsinki and approved by local Ethics Committees for medical investigations in Estonia and in Finland. The parents of all participants provided written informed consent for the study.

3. Results

3.1. General characteristics of the participants

During the study period 29 children developed CD: nine children (two Estonian and seven Finnish children) in the BC and 20 children (six Estonian and 14 Finnish children) in the YCC. None of them had IgA deficiency and all 29 were positive for IgA-tTG and EMA. One Finnish child with CD in YCC later developed diabetes. In addition, two Finnish children in the YCC tested positive for both IgA-tTG and EMA, however, a small intestine biopsy did not confirm the diagnosis of CD. All children with CD and those of the control group had been born full-term (gestational age between 37 and 42 weeks). Twenty-three children with CD (79%) were autumn-, winter- or spring-born (from September to May). Five children in the CD group (17%) and six children in the control group (20%) had been delivered by Caesarean section while all the remaining children had been born vaginally. There were no statistical differences in mean birth weight either between the CD and the control groups in the BC (3632 g vs 3695 g) or in the YCC (3520 g vs 3734 g), or between the Estonian and Finnish children. There were more girls than boys with CD (19 vs 10, P = 0.04). In the YCC there were more girls than boys with CD (15 vs five), but not in the BC (four vs five) (P = 0.20). In the CD group, 28 children carried the DR3-DQ2 haplotype (97%) and one child in the YCC carried the DR4-DQ8 haplotype. The mean age at initial seroconversion to IgA-tTG positivity in the BC was 3.0 (95% CI 2.5–3.6) years in Estonia and 2.3 (95% CI 1.6–2.9) years in Finland (P = 0.12). In the YCC, five out of six Estonian children (83%) and eleven out of fourteen Finnish children (79%) showed positive IgA-tTG at their first visit at the age of 3 years. There was no statistically significant difference in mean IgA-tTG level at the time of the diagnosis between the Estonian and Finnish children with CD either in the BC (68.5 EliA U/ml (95% CI 0.6–0.85) vs 261.2 EliA U/ml (95% CI 0.6–19.1), P = 0.67) or in the YCC (1045.9 EliA U/ml (95% CI 0.27–49.9) vs 812.8 EliA U/ml (95% CI 87.8–1537.8), P = 0.78). The IgA-tTG level of 18 out of 29 children with CD was more than 10 times as high as the cut-off level for antibody positivity (>100 EliA U/ml) in 63% of the Estonian and in 62% of the Finnish children with CD.

3.2. Cumulative incidence

The cumulative incidence of CD in the two countries was not significantly different for the BC or for the YCC during the study period. In the BC the cumulative incidence was 0.12% (95% CI 0.02–0.49) in Estonia and 0.53% (95% CI 0.23–1.13) in Finland (P = 0.10) (the incidence rate 0.4 cases per 1000 person-years and 1.8 cases per 1000 person-years, respectively), while in the YCC it was 0.4% (95% CI 0.18–1.0) and 1% (95% CI 0.58–1.7) (the incidence rate 2.2 cases per 1000 person-years and 5.1 cases per 1000 person-years, respectively), (P = 0.12). However, when the cohorts were combined the cumulative incidence of childhood CD was significantly higher in Finland than in Estonia (0.77% vs 0.27%; P = 0.01) (the incidence rate 1.0 cases per 1000 person-years and 3.1 cases per 1000 person-years, respectively).

3.3. Early feeding

In the BC information about the duration of breastfeeding in weeks was available for all children, while in the YCC this information (in months) was available for 18 out of the 20 children (Table 1). There was no statistical difference in the total duration of breastfeeding between the children with CD and the control children in the BC or in the YCC (Table 1). Nor was there any significant difference in the duration of exclusive breastfeeding between the groups in the BC. In the BC, the age at which wheat, barley or rye was introduced was not statistically different between the CD and the control groups (Table 2). The mean age when complementary food was introduced was similar in both groups (4.4 months). In the YCC, information about age at the introduction of cereal or complementary food was not collected.

### Table 1

<table>
<thead>
<tr>
<th></th>
<th>N</th>
<th>Mean duration</th>
<th>Minimum and maximum</th>
<th>95% CI</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>BC CD</td>
<td>9</td>
<td>35.7 weeks</td>
<td>6 – 96 weeks</td>
<td>13.9–57.4</td>
<td>0.45</td>
</tr>
<tr>
<td>BC control</td>
<td>9</td>
<td>43.7 weeks</td>
<td>1 – 84 weeks</td>
<td>24.6–62.7</td>
<td></td>
</tr>
<tr>
<td>YCC CD</td>
<td>18</td>
<td>8.5 months</td>
<td>0 – 24 months</td>
<td>5.7–11.4</td>
<td>0.12</td>
</tr>
<tr>
<td>YCC control</td>
<td>18</td>
<td>11.6 months</td>
<td>2 – 22 months</td>
<td>8.9–11.9</td>
<td></td>
</tr>
</tbody>
</table>

### Table 2

<table>
<thead>
<tr>
<th></th>
<th>CD (N)</th>
<th>95% CI</th>
<th>Control (N)</th>
<th>95% CI</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Wheat</td>
<td>6.4 (9)</td>
<td>5.6–7.2</td>
<td>5.8 (8)</td>
<td>4.9–6.7</td>
<td>0.28</td>
</tr>
<tr>
<td>Barley</td>
<td>6.3 (8)</td>
<td>5.3–7.2</td>
<td>5.6 (8)</td>
<td>4.8–6.5</td>
<td>0.20</td>
</tr>
<tr>
<td>Rye</td>
<td>7.4 (7)</td>
<td>5.8–8.9</td>
<td>5.9 (8)</td>
<td>4.7–7.1</td>
<td>0.10</td>
</tr>
</tbody>
</table>
3.4. Infections and antibiotic treatment

In the BC, children with CD had significantly more episodes of infections with fever by the age of 12 months compared to the controls (3.4 vs 1.4; \( P = 0.04 \)). During the following months these differences remained non-significant (Fig. 1). In the BC there was no significant difference in the number of episodes of gastroenteritis between the CD and the control groups during the first 3 years of life (1 vs 0.9, \( P = 0.82 \)). No difference was seen in the use of antibiotics between the groups, either.

In the YCC, there were no statistical differences in the number of episodes of infections with fever (2.2 vs 3.3) or antibiotic therapy (1.1 vs 1.0) between the groups. Data for the first 3 years of life was collected retrospectively. By the age of 3 years children both in the CD group and in the control group had had 3.2 episodes of otitis (\( P = 0.69 \)) and 0.5 and 0.8 episodes of gastroenteritis, respectively (\( P = 0.73 \)).

3.5. Vaccinations

In the BC and in the YCC, all children in both groups were at least partly vaccinated according to the local vaccination schedule, except for one Finnish control child in the BC and one Finnish child with CD and one Finnish control child in the YCC, who were not vaccinated.

4. Discussion

The present study compares the cumulative incidence of CD and a set of risk factors for Estonia and Finland, the two neighbouring countries participating in the DIABIMMUNE project. The project was initiated to test the hygiene hypothesis for T1D and for other immune-mediated diseases by using two longitudinal cohorts of children that were followed from birth to 3 years of age and from 3 to 5 years of age.

Previous studies have revealed significant unexplained differences in the prevalence of adulthood CD across Europe [4]. Some differences have been detected also in the prevalence of childhood CD between European countries [5,27,28]. However, the results are not well comparable as different methods have been applied and different study populations have been studied. In the present study we used the same strategy for two adjacent countries to identify new patients with CD and the obtained results are well comparable. Since the antibody assays for CD screening were performed in a single laboratory, the theoretical chance of revealing new cases was equal for both populations. In addition, Ress et al. [29] showed that the diagnostic accuracy and sensitivity of the fully automated fluoroenzyme immunoassay method on ImmunoCAP is similar to the traditional ELISA. Based on this approach, we found that the cumulative incidence of CD in children from birth to the age of 5 was almost three times lower in Estonia than in Finland (0.27% vs 0.77%). A similar difference between Estonia and Finland was also noted for another immune-mediated disease, T1D [30]. The potential reasons for this may be related to different environmental factors, since differences in the risk associated genetic factors between the two populations can hardly explain the difference. The frequency of the major CD risk haplotype was actually slightly higher among the Estonian than among the Finnish population [31]. Environmental factors may start playing a role in susceptibility to immune-mediated diseases already in utero [32].

The Finnish children in the BC tended to develop positive tTG antibodies earlier compared to their Estonian peers. The IgA-tTG became positive at a mean age of 3.0 years in Estonia and at 2.3 years in Finland. Although no earlier studies have compared CD-associated autoantibodies between Estonia and Finland, it has been found that the anti-reticulin autoantibody frequency is lower for Estonian young adults compared to Swedish young adults [33], Sweden being a country with an economic and social background similar to that of Finland. The above findings support the lower prevalence of autoimmunity and autoimmune diseases in Estonia compared to the Nordic countries.

The ESPGHAN and the European Food Safety Authority recommend to avoid gluten introduction to children less than 4 months of age and more than 7 months of age and to introduce gluten while the infant is still breastfed [34,35]. According to the American Academy of Pediatrics, complementary food should be introduced between 4 and 6 months of age [36]. However, recent studies suggest that these recommendations need to be reviewed [18,19,37]. According to current recommendations in Estonia and Finland, complementary food should be introduced when the infant has reached the age of 6 months, although small tasting portions may be given after the age of 4 months. In our study we did not note any significant difference in the mean age at the time of cereal introduction between the CD and the control groups. Nor was there any difference in the total duration of breastfeeding between the children with CD and the control children either in the BC or in the YCC. These findings indicate that differences in early feeding may not be an important risk factor in modulating the development of CD.

There are more important risk factors that may be associated with differences in cereal consumption and in the quantity and
character of ingested gluten or gluten-related prolamines. Unfortunately, we could not calculate exact cereal consumption or evaluate the quantity of gluten consumed by our study population.

Previous epidemiological studies have suggested that neonatal and early infections may increase the risk of CD [38,39]. Mylëus et al. reported that three or more infectious episodes during the first 6 months increased the risk of CD later in life [38] while the type of infection was irrelevant. Also a more recent prospective large-scale population-based cohort study by Mårlid et al. [40] found that early life infections may play a role in the development of CD. Our study supports this finding. In the BC there were more infections with fever in the CD group. Similarly to a study by Mylëus et al. [38], the episodes of infections were reported by the parents in our study. In the YCC the number of infections did not differ between the CD children and the controls. However, in the YCC the parents were asked to report retrospectively all their children's infections from birth up to the age of 3 years at the initial study centre visit. In the BC, where follow-up visits were conducted with shorter intervals, the parents were asked to report infections in real time in the study diary. In contrast to Stene et al. [39], we did not find any difference in the frequency of gastroenteritis between the CD and the control groups. The exact molecular mechanisms by which infections increase the risk of CD have not been defined. One reason could be the increased mucosal permeability of not only the intestine but also of the respiratory tract [41,42]. The latter circumstance may increase susceptibility to respiratory tract infections [43,44]. According to our data, it is not likely that differences in vaccination between the study groups and the two countries would cause differences in autoimmunity.

The major strengths of the present study are its prospective design (with part of data obtained retrospectively) and the fact that both centres in the two countries involved used identical protocols for follow-up and diagnosis. In addition, all CD antibody analyses were carried out in one laboratory and in all CD cases the diagnosis was confirmed by a biopsy of the small intestine. However, the study has also some limitations. The number of cases is relatively modest, limiting the statistical power of the study. The relatively short follow-up period (up to 3 years in the BC and from 3 to 5 years in the YCC) prevented us from detecting all childhood CD cases. Some data (early feeding and early infections in the YCC) was collected retrospectively, which may have affected its quality.

5. Conclusion

There is a significant difference in the 5-year cumulative incidence of childhood CD between Estonia and Finland, which is higher in the latter country. The children from Finland tended to develop IgA-tTG antibodies earlier than the children from Estonia. No difference was seen in the duration of breastfeeding or age at cereal introduction between the children with CD and the control children. Sequential infections early in life may increase the risk for developing CD, although we cannot fully rule out that this was a chance finding.

Conflict of interest
None declared.

Funding

The project was funded by the European Commission (7th Framework Programme, project 202063), the Estonian Research Council grant IUT20-43 and the Academy of Finland (the Centre of Excellence in Molecular Systems Immunology and Physiology Research, 2012–2017, Decision Nos. 250114 and 284597).

Acknowledgements

The authors like to thank Ija Talja, MSc, for performing the EMA tests.

Appendix A. Investigators of DIABIMMUNE Study Group

Mikael Knip, Children’s Hospital, University of Helsinki, Finland
Katrina Koski, Institute of Clinical Medicine, University of Helsinki, Finland
Matti Koski, Institute of Clinical Medicine, University of Helsinki, Finland
Taina Härkönen, Children’s Hospital, University of Helsinki, Finland
Heli Siljander, Children’s Hospital, University of Helsinki, Finland
Sampa Ryhänen, Children’s Hospital, University of Helsinki, Finland
Anu-Maaria Hämäläinen, Jorvi Hospital, Helsinki University Central Hospital, Finland
Anne Ormisson, Children’s Clinic, Tartu University Hospital, Finland
Aleksandr Peet, Department of Pediatrics, Tartu University Hospital, Finland
Vallo Tillmann, Department of Pediatrics, Tartu University Hospital, Finland
Valentina Ulich, Ministry of Health and Social Development, Karelian Republic of the Russian Federation, Russia
Elena Kuzmicheva, Ministry of Health and Social Development, Karelian Republic of the Russian Federation, Russia
Sergei Mokurov, Ministry of Health and Social Development, Karelian Republic of the Russian Federation, Russia
Svetlana Markova, Children’s Republic Hospital, Karelian Republic of the Russian Federation, Russia
Svetlana Pylova, Children’s Republic Hospital, Karelian Republic of the Russian Federation, Russia
Marina Isaková, Perinatal Center, Karelian Republic of the Russian Federation, Russia
Elena Shakurova, Perinatal Center, Karelian Republic of the Russian Federation, Russia
Vladimir Petrov, Maternity Hospital N8 1, Petrozavodsk, Russia
Natalya V. Dorshakova, Petrozavodsk State University, Russia
Tatyana Karapetyan, Petrozavodsk State University, Russia
Tatyana Varlamova, Petrozavodsk State University, Russia
Jorma Ionen, Immunogenetics Laboratory, University of Turku, Finland
Department of Clinical Microbiology, University of Eastern Finland, Kuopio, Finland
Minna Kiviniemi, Immunogenetics Laboratory, University of Turku, Finland
Kristi Alnek, Department of Immunology, University of Tartu, Finland
Heiri Janson, Department of Immunology, University of Tartu, Finland
Raivo Uibo, Department of Immunology, University of Tartu, Finland
Erika von Mutius, Children’s Hospital, Ludwig Maximilians University, Munchen, Germany
Juliane Weber, Children’s Hospital, Ludwig Maximilians University, Munchen, Germany
Helena Ahlfor, Turku Centre of Biotechnology, University of Turku and Åbo Akademi, Finland
Henna Kallionpää, Turku Centre of Biotechnology, University of Turku and Åbo Akademi, Finland
Essi Laajala, Turku Centre of Biotechnology, University of Turku and Åbo Akademi, Finland
Riitta Lahesmaa, Turku Centre of Biotechnology, University of Turku and Åbo Akademi, Finland


Harri Lähdesmäki, Turku Centre of Biotechnology, University of Turku and Åbo Akademi, Finland
Robert Moulder, Turku Centre of Biotechnology, University of Turku and Åbo Akademi, Finland
Janne Nieminen, Department of Vaccination and Immune Protection, National Institute for Health and Welfare, Helsinki, Finland
Terttu Ruokokanta, Department of Vaccination and Immune Protection, National Institute for Health and Welfare, Helsinki, Finland
Otti Vaara, Department of Vaccination and Immune Protection, National Institute for Health and Welfare, Helsinki, Finland
Hanna Honkanen, Department of Virology, University of Tampere and Tampere University Hospital, Finland
Heikki Hyötty, Department of Virology, University of Tampere and Tampere University Hospital, Finland
Anita Kondrashova, Department of Virology, University of Tampere and Tampere University Hospital, Finland
Sami Oikarinen, Department of Virology, University of Tampere and Tampere University Hospital, Finland
Hermie J.M. Harmesen, University Medical Center Groningen, Finland
Marcus C. de Goffau, University Medical Center Groningen, Finland
Gjal Wellens, University Medical Center Groningen, Finland
Kirsi Alaluhta, Department for Welfare and Health Promotion, National Institute for Health and Welfare, Helsinki, Finland
Suvi M. Virtanen, Department for Welfare and Health Promotion, National Institute for Health and Welfare, Helsinki, Finland

References


1301

1296


1301